All In Biotech

Drug Trial Radar · NCT01896479

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 247 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

247

Actual

Start

Feb 25, 2015

Primary completion

Jul 15, 2020

Study completion Jan 31, 2035

Sponsor

Lead sponsor
ExelixisIndustry
Sponsor type
Industry
First posted
Jul 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.

Conditions

  • Medullary Thyroid Cancer

Interventions

  • Cabozantinib (XL184) 140 mgDrug

  • Cabozantinib (XL184) 60 mgDrug

  • Placebo tabletDrug

  • Placebo capsuleDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Median time of follow-up (from the date of randomization of the first participant through primary data cut off [15 July 2020]) was 30.2 months

Locations

49 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    St Leonards, New South Wales, Australia

  • Site not named

    Herston, Queensland, Australia

  • Site not named

    Kurralta Park, South Australia, Australia

  • Site not named

    Parkville, Victoria, Australia

  • Site not named

    Toronto, Canada

  • Site not named

    Québec, Quebec, Canada

  • Site not named

    Osijek, Croatia

  • Site not named

    Zagreb, Croatia

  • Site not named

    Zagreb, Croatia

  • Site not named

    Dijon, France

  • Site not named

    Paris, France

  • Site not named

    Strasbourg, France

  • Site not named

    Bordeaux, Gironde, France

  • Site not named

    Angers, Maine-et-Loire, France

  • Site not named

    Lyon, Rhône, France

  • Site not named

    Villejuif, Val-de-Marne, France

  • Site not named

    Budapest, Hungary

  • Site not named

    Debrecen, Hungary

  • Site not named

    Jerusalem, Israel

  • Site not named

    Petah Tikva, Israel

  • Site not named

    Safed, Israel

  • Site not named

    Milan, Italy

  • Site not named

    Padua, Italy

  • Site not named

    Torino, Italy

  • Site not named

    Catania, CT, Italy

  • Site not named

    Roma, RM, Italy

  • Site not named

    Siena, SI, Italy

  • Site not named

    Pisa, Tuscany, Italy

  • Site not named

    Groningen, Netherlands

  • Site not named

    Amsterdam, North Holland, Netherlands

  • Site not named

    Leiden, South Holland, Netherlands

  • Site not named

    Poznan, Greater Poland Voivodeship, Poland

  • Site not named

    Gliwice, Silesian Voivodeship, Poland

  • Site not named

    Bucharest, Romania

  • Site not named

    Bucharest, Romania

  • Site not named

    Cluj-Napoca, Romania

  • Site not named

    Timișoara, Romania

  • Site not named

    Novosibirsk, Russia

  • Site not named

    Obninsk, Russia

  • Site not named

    Saint Petersburg, Russia

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.